001 BR July 2020

COVID-19 pandemic catalyses real-world oncology data uptake

“By necessity, COVID-19 has pushed the cancer clinical trial community out of its comfort zone to rapidly deploy remote assessments and digital health technology, [prompting] unprecedented collaboration to explore the use of real-world data. We cannot lose this opportunity to learn and advance our knowledge of the strengths and limitations of decentralized trials and real-world […]

Read More
001 VN Jul 2020

Real-world evidence (RWE) market worth over £1bn by 2023

Oncology segment accounted for the largest share of the RWE solutions market in 2017 The rising focus on end-to-end RWE services and growth within emerging markets are expected to provide further business opportunities for players operating in the RWE market Click here to learn more About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence […]

Read More
001 DC July 2020

Adjuvant immunotherapy conferred a 93% survival at 1 year for patients with resectable melanoma at the highest risk of relapse

The analysis captures the first survival data from the National Cancer Database (NCDB) since the FDA’s 2015 approval of ipilimumab (Yervoy) following curative intent surgery in stage III patients. Survival data were available for the 4,094 patients diagnosed in 2015, of which 1,014 were treated with immunotherapy. At 1 year, 93% of patients that received surgery plus […]

Read More